Cargando…
Sclerocarya birrea (Marula) Extract Inhibits Hepatic Steatosis in db/db Mice
Non-alcoholic fatty liver disease (NAFLD) is a spectrum of hepatic metabolic perturbations ranging from simple steatosis to steatohepatitis, cirrhosis and hepatocellular carcinoma. Currently, lifestyle modifications to reduce weight gain are considered the most effective means of preventing and trea...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8998011/ https://www.ncbi.nlm.nih.gov/pubmed/35409465 http://dx.doi.org/10.3390/ijerph19073782 |
_version_ | 1784684840858157056 |
---|---|
author | Mabasa, Lawrence Kotze, Anri Shabalala, Samukelisiwe Kimani, Clare Gabuza, Kwazi Johnson, Rabia Sangweni, Nonhlakanipho F. Maharaj, Vinesh Muller, Christo J. F. |
author_facet | Mabasa, Lawrence Kotze, Anri Shabalala, Samukelisiwe Kimani, Clare Gabuza, Kwazi Johnson, Rabia Sangweni, Nonhlakanipho F. Maharaj, Vinesh Muller, Christo J. F. |
author_sort | Mabasa, Lawrence |
collection | PubMed |
description | Non-alcoholic fatty liver disease (NAFLD) is a spectrum of hepatic metabolic perturbations ranging from simple steatosis to steatohepatitis, cirrhosis and hepatocellular carcinoma. Currently, lifestyle modifications to reduce weight gain are considered the most effective means of preventing and treating the disease. The aim of the present study was to determine the therapeutic benefit of Sclerocarya birrea (Marula leaf extract, MLE) on hepatic steatosis. Obese db/db mice were randomly stratified into the obese control, metformin (MET) or MLE-treated groups. Mice were treated daily for 29 days, at which point all mice were euthanized and liver samples were collected. Hematoxylin and eosin staining was used for histological assessment of the liver sections, while qRT-PCR and Western blot were used to determine hepatic mRNA and protein expression, respectively. Thereafter, the association between methylenetetrahydrofolate reductase (Mthfr a key enzyme in one-carbon metabolism and DNA-methylation-induced regulation of gene transcription) and lipogenic genes was evaluated using Pearson’s correlation coefficient. Mice treated with MLE presented with significantly lower body and liver weights as compared with the obese control and MET-treated mice (p ≤ 0.05). Further, MLE treatment significantly inhibited hepatic steatosis as compared with the obese control and MET-treated mice (p ≤ 0.05). The reduced lipid accumulation was associated with low expression of fatty acid synthase (Cpt1; p ≤ 0.05) and an upregulation of the fatty acid oxidation gene, carnitine palmitoyltransferase (Cpt1; p ≤ 0.01), as compared with the obese control mice. Interestingly, MLE treatment improved the correlation between Mthfr and Cpt1 mRNA expression (r = 0.72, p ≤ 0.01). Taken together, the results suggest that Marula leaf extracts may inhibit hepatic steatosis by influencing the association between Mthfr and genes involved in hepatic lipid metabolism. Further studies are warranted to assess DNA methylation changes in lipid metabolism genes. |
format | Online Article Text |
id | pubmed-8998011 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89980112022-04-12 Sclerocarya birrea (Marula) Extract Inhibits Hepatic Steatosis in db/db Mice Mabasa, Lawrence Kotze, Anri Shabalala, Samukelisiwe Kimani, Clare Gabuza, Kwazi Johnson, Rabia Sangweni, Nonhlakanipho F. Maharaj, Vinesh Muller, Christo J. F. Int J Environ Res Public Health Article Non-alcoholic fatty liver disease (NAFLD) is a spectrum of hepatic metabolic perturbations ranging from simple steatosis to steatohepatitis, cirrhosis and hepatocellular carcinoma. Currently, lifestyle modifications to reduce weight gain are considered the most effective means of preventing and treating the disease. The aim of the present study was to determine the therapeutic benefit of Sclerocarya birrea (Marula leaf extract, MLE) on hepatic steatosis. Obese db/db mice were randomly stratified into the obese control, metformin (MET) or MLE-treated groups. Mice were treated daily for 29 days, at which point all mice were euthanized and liver samples were collected. Hematoxylin and eosin staining was used for histological assessment of the liver sections, while qRT-PCR and Western blot were used to determine hepatic mRNA and protein expression, respectively. Thereafter, the association between methylenetetrahydrofolate reductase (Mthfr a key enzyme in one-carbon metabolism and DNA-methylation-induced regulation of gene transcription) and lipogenic genes was evaluated using Pearson’s correlation coefficient. Mice treated with MLE presented with significantly lower body and liver weights as compared with the obese control and MET-treated mice (p ≤ 0.05). Further, MLE treatment significantly inhibited hepatic steatosis as compared with the obese control and MET-treated mice (p ≤ 0.05). The reduced lipid accumulation was associated with low expression of fatty acid synthase (Cpt1; p ≤ 0.05) and an upregulation of the fatty acid oxidation gene, carnitine palmitoyltransferase (Cpt1; p ≤ 0.01), as compared with the obese control mice. Interestingly, MLE treatment improved the correlation between Mthfr and Cpt1 mRNA expression (r = 0.72, p ≤ 0.01). Taken together, the results suggest that Marula leaf extracts may inhibit hepatic steatosis by influencing the association between Mthfr and genes involved in hepatic lipid metabolism. Further studies are warranted to assess DNA methylation changes in lipid metabolism genes. MDPI 2022-03-22 /pmc/articles/PMC8998011/ /pubmed/35409465 http://dx.doi.org/10.3390/ijerph19073782 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Mabasa, Lawrence Kotze, Anri Shabalala, Samukelisiwe Kimani, Clare Gabuza, Kwazi Johnson, Rabia Sangweni, Nonhlakanipho F. Maharaj, Vinesh Muller, Christo J. F. Sclerocarya birrea (Marula) Extract Inhibits Hepatic Steatosis in db/db Mice |
title | Sclerocarya birrea (Marula) Extract Inhibits Hepatic Steatosis in db/db Mice |
title_full | Sclerocarya birrea (Marula) Extract Inhibits Hepatic Steatosis in db/db Mice |
title_fullStr | Sclerocarya birrea (Marula) Extract Inhibits Hepatic Steatosis in db/db Mice |
title_full_unstemmed | Sclerocarya birrea (Marula) Extract Inhibits Hepatic Steatosis in db/db Mice |
title_short | Sclerocarya birrea (Marula) Extract Inhibits Hepatic Steatosis in db/db Mice |
title_sort | sclerocarya birrea (marula) extract inhibits hepatic steatosis in db/db mice |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8998011/ https://www.ncbi.nlm.nih.gov/pubmed/35409465 http://dx.doi.org/10.3390/ijerph19073782 |
work_keys_str_mv | AT mabasalawrence sclerocaryabirreamarulaextractinhibitshepaticsteatosisindbdbmice AT kotzeanri sclerocaryabirreamarulaextractinhibitshepaticsteatosisindbdbmice AT shabalalasamukelisiwe sclerocaryabirreamarulaextractinhibitshepaticsteatosisindbdbmice AT kimaniclare sclerocaryabirreamarulaextractinhibitshepaticsteatosisindbdbmice AT gabuzakwazi sclerocaryabirreamarulaextractinhibitshepaticsteatosisindbdbmice AT johnsonrabia sclerocaryabirreamarulaextractinhibitshepaticsteatosisindbdbmice AT sangweninonhlakaniphof sclerocaryabirreamarulaextractinhibitshepaticsteatosisindbdbmice AT maharajvinesh sclerocaryabirreamarulaextractinhibitshepaticsteatosisindbdbmice AT mullerchristojf sclerocaryabirreamarulaextractinhibitshepaticsteatosisindbdbmice |